


**Supplemental table 1:** Mean (CV%) PK parameters of SAR3419 at 55 mg/m<sup>2</sup> obtained after first and last administration.

Study schedule	N	C <sub>max</sub> (µg/mL)	AUC <sub>0-τ</sub> <sup>a</sup> (µg.day/mL)	t <sub>1/2Z</sub> (day)	CL <sub>ss</sub> (L/day)	V <sub>ss</sub> (L)	C <sub>avg</sub> (µg/mL)
<b>1<sup>st</sup> SAR3419 administration (Week 1)</b>							
Weekly optimized	40	28.4 (27)	103 (30)	-	-	-	14.7 (30)
<b>Last SAR3419 administration (5<sup>th</sup> to 12<sup>th</sup> administration)</b>							
Weekly	14	50.5 (31)	227 (37)	8.96 (41)	0.514 (44)	6.39 (52)	32.4 (37)
Optimized	9	41.6 (26)	260 (31)	7.99 (27)	0.438 (56)	4.34 (28)	18.6 (31)

<sup>a</sup> : τ corresponds to the dosing interval: 7 days after the first administration whatever the study schedule and the last weekly administration and 14 days after the last administration in the optimized schedule.

**Supplemental figure 1:** SAR3419  $C_{trough}$  observed during repeated intravenous infusion of SAR3419 using weekly or optimized schedules



**Supplemental table 2:** relationship between CD19 expression, proliferation (KI67), mitosis (pHH3) and p53 status with observed observed responses at the MTD during the optimized schedule

		CD19 - DAKO		KI67	p53	pHistone H3	Lymphoma subtype
		intensity	% of positive cells	% of positive cells	% of positive cells	% of positive cells	
CR	250-003-110	3	90	50	< 10 %	5%	Follicular GII
Cru	250-004-105	1	30	5	< 10 %	< 1 %	Follicular grade unknown
	250-006-112	3	90	40	< 10 %	< 1 %	DLBC
PR	250-005-103	3	90	60	< 10 %	1%	DLBC
	250-005-211	2	90	NI	NI	NI	MALT
SD	250-004-106	1	70	50	< 10 %	NI	Follicular G IIIB transforming in DLBC
	250-004-111			10	No slide	No slide	follicular G II
	250-006-113	1	50	70	< 10 %	1%	DLBC
	250-004-204	NI		NI	NI	NI	Follicular grade unknown
	250-006-208	2	80	1	< 10 %	0	MALT
PD	250-006-108	2	50	80	> 10 %	1%	DLBC
	250-006-109	1	10	0	< 10 %	0	DLBC
	250-004-205	3	90	40	< 10 %	1%	follicular G II